The innate immune response elicited by activation of TLRs (Toll-like receptors) plays an important role in the pathogenesis of atherosclerosis. We hypothesized that cardiovascular risk factors are associated with the activation status of the innate immune system. We therefore assessed the responsiveness of TLRs on circulating cells in two groups of patients with established atherosclerosis and related this to the presence of cardiovascular risk factors. TNF (tumour necrosis factor)-α release induced by TLR2 and TLR4 activation was measured in patients with established coronary [PCI (percutaneous coronary intervention) study, n = 78] or carotid artery disease [CEA (carotid endarterectomy) study, n = 104], by stimulating whole blood samples with lipopolysaccharide (TLR4 ligand) and Pam 3 CSK 4 [tripalmitoylcysteinylseryl-(lysyl) 4 ; TLR2 ligand]. As an early activation marker, CD11b expression was measured by flow cytometry on CD14 + cells. Obesity was the 'only' risk factor that correlated with the TLR response. In both studies, obese patients had significantly higher TNF-α levels after stimulation of TLR2 compared with non-obese patients [16.9 (7.7-49.4) compared with 7.5 (1.5-19.2) pg/ml (P = 0.008) in coronary artery disease and 14.6 (8.1-28.4) compared with 9.5 (6.1-15.7) pg/ml (P = 0.015) in carotid artery disease; values are medians (interquartile range)]. Similar results were obtained following TLR4 stimulation. The enhanced inflammatory state in obese patients was also confirmed by a significant increased expression of the activation marker CD11b on circulating monocytes. In conclusion, obesity is associated with an enhanced TLR response in patients suffering from established atherosclerotic disease.
INTRODUCTION
Atherosclerosis is considered as a generalized chronic inflammatory disorder of the vascular tree [1, 2] . Patients suffering from chronic inflammatory diseases such as systemic lupus erythematosus or rheumatoid arthritis have an increased risk for developing atherosclerosis [3, 4] . A potential clue for the underlying mechanisms of this increased prevalence might be the chronic inflammatory state to which patients are subjected. This enhanced systemic inflammatory state drives the successive activation of endothelial cells, leucocyte adherence and migration through the arterial wall leading to the production of pro-inflammatory cytokines. The relevance of smoking, diabetes, hypercholesterolaemia and hypertension in the development of atherosclerosis is evident [5] . A possible explanation for the increased risk of atherosclerosis, in the presence of these traditional risk factors, is the enhanced activation of the immune system.
Obesity is a worldwide increasing problem, especially in Western societies [6] [7] [8] . Obesity is associated with an increased risk of acquiring traditional cardiovascular risk factors, potentiating the development of atherosclerosis and concomitant cardiovascular complications [9] [10] [11] . Obesity is also directly related to the development and progression of atherosclerosis [12] [13] [14] [15] . Several studies have provided evidence that adipose tissue is not just an energy storage depot but also a source of cytokineproducing inflammatory cells [16] [17] [18] [19] [20] .
TLRs (Toll-like receptors), which are part of the innate immune system, are pattern-recognizing receptors forming the first line of defence, quickly reacting to evolutionarily conserved pathogens [21] . However, endogenous ligands such as extra domain A, heat-shock proteins, fibronectin and NEFAs (non-esterified 'free' fatty acids) are also able to activate these receptors, resulting into a pro-inflammatory cytokine response. TLRs are found in atherosclerotic tissue but also have shown to play a role in lipid uptake in macrophages and are expressed on circulating monocytes [22, 23] . We and others have shown the importance of these receptors in the initiation and progression of atherosclerosis [24] [25] [26] [27] . Responsiveness upon ligation of these receptors can be measured in whole blood, ex vivo. Previously, we showed that responsiveness altered with different severities of coronary artery stenosis [28] . Others showed that this response was elevated in patients having unstable angina pectoris or acute MI (myocardial infarction) compared with patients with stable angina [29, 30] .
Considering the central role of the TLR in atherosclerosis development, we hypothesized that cardiovascular risk factors are associated with an altered activation status of the innate immune system, reflected by differences in TLR responsiveness. We assessed the TLR response in patients with established atherosclerosis in two different territories: atherosclerosis of the coronary [PCI (percutaneous coronary intervention) study] and of the carotid artery [CEA (carotid endarterectomy) study] and related this to the presence of cardiovascular risk factors. In addition, we measured expression of the early activation marker CD11b on circulating monocytes.
We demonstrate that obesity is associated with an altered TLR response in patients with established atherosclerosis of the coronary or carotid artery.
MATERIALS AND METHODS

Patients
Two cohorts of patients were analysed for the present study. Both studies were approved by the local medical committee board, and informed consents were obtained.
The first cohort consisted of 100 subsequent patients scheduled for PCI study at the University Medical Centre Utrecht.
The second group consisted of 111 consecutive patients scheduled for CEA study at the University Medical Centre Utrecht and at the St Antonius Hospital, Nieuwegein. This last patient group is part of the Atheroexpress Biobank study [31] .
Clinical data were obtained from patients' medical file records and from preprocedural filled-in questionnaires. Risk factors were scored as follows: hypertension: the use of one or more antihypertensive drugs (>3 months before intervention); hypercholesterolaemia: the use of statins for at least 3 months before intervention; diabetes: the use of anti-diabetic medication (>3 months before intervention); positive family history of heart disease: more than one family member with a cardiac event [MI, AP (angina pectoris) or CABG (coronary artery bypass graft surgery)] <60 years. Obese patients were classified as having a BMI (body mass index) >25.0 and nonobese patients as having a BMI 25.0. Smoking status was derived from the preoperative intake questionnaire of the Department of Anesthesiology.
Blood sampling
PCI study
Whole blood samples were drawn in LH (lithiumheparin) and EDTA-anti-coagulated tubes before PCI. To prevent premature leucocyte activation, all tubes were kept on ice until further processing. The effect of short-term preservation on ice on cytokine production was evaluated before initiation of this study. This short-term preservation did not influence the experiments. A portion (100 μl) of blood was stimulated with 100 μl of the synthetic TLR2 ligand Pam 3 CSK 4 [tripalmitoylcysteinylseryl-(lysyl) 4 ; Novabiochem] at 500 ng/ml and 100 μl of the TLR4 ligand LPS (lipopolysaccharide; derived from Escherichia coli serotype O55:B5; Sigma) at 10 ng/ml. Samples were incubated o/n (overnight) at 37
• C and 5% CO 2 . After o/n incubation, samples were centrifuged at 1000 rev./min for 5 min, and supernatants were collected and stored at − 20
• C until further processing. As a surrogate of the TLR2 and TLR4 response, TNF (tumour necrosis factor)-α was measured in the supernatants using an ELISA, according to the manufacturer's protocol (Pelikine-compact; Sanquin). TNF-α levels were corrected for white blood cell count, which was measured using a haematology analyser (Celldyn 1700; Abbott Diagnostics).
In 
CEA study
Whole blood samples were drawn before incision, immediately after anaesthesia. In a substudy, the effect of anaesthetics was investigated on TLR activation. The anaesthetics did not influence the TNF-α levels (results not shown). Samples were stored in heparinized tubes and immediately processed at the laboratory. Blood samples were stimulated by using the same protocol as used in the PCI study, but, instead of o/n incubation, samples were stimulated for 2 h. As a surrogate of the TLR2 and TLR4 response, TNF-α, IL (interleukin) 6 and IL8 were measured in the supernatants using a multiplex immunoassay system, according to the manufacturer's protocol, (BioPlex 200; Bio-Rad Laboratories). TNF-α, IL6 and IL8 levels were corrected for white blood cell count.
In heparin-anti-coagulated blood samples, TLR2, TLR4 and CD11b expression on CD14 + monocytes were examined by flow cytometry (Cytomics FC500; Beckman Coulter). Whole blood samples were stained for CD14 (RPE-Cy5) combined with TLR2 (FITC) and TLR4 (PE) (Serotec) and CD11b [PE-Cy7 (indotricarbocyanine)] (eBiosciences). TLR2, TLR4 and CD11b expression levels are represented as MFI on CD14 + monocytes. CD11b expression on CD14 + cells was also measured after stimulation. A portion (100 μl) of heparinized whole blood was stimulated with 100 μl of (i) PBS (negative control), (ii) Pam 3 CSK 4 (500 ng/ml) (TLR2 stimulation), (iii) LPS (100 ng/ml) (TLR4 stimulation) and (iv) PMA (non-specific stimulation). Stimulated blood samples were incubated for 30 min at 37
• C and 5 % CO 2 .
Exclusions
In the PCI study, 22 patients were excluded for analysis: nine patients were suffering from acute MI within 24 h prior to PCI, 12 patients suffered from chronic inflammatory disorders receiving corticosteroid drugs and, finally, one patient was excluded because information about traditional risk factors was lacking.
In the CEA study, seven patients were excluded for analysis: four patients with a chronic inflammatory disorder receiving corticosteroid drugs preoperatively and three patients because white blood cell counts were not performed.
Statistics
Values are medians [IQR (interquartile range)], unless otherwise stated. TNF-α levels, mean fluorescence levels and CRP levels were not normally distributed. After ln-transformation, the data were normally distributed. Differences between two independent variables were calculated with an independent-sample Student's t test. Differences between three or more independent variables were calculated by using one-way ANOVA. Differences between two dichotomous values were calculated using a χ 2 test. Differences between two continuous variables were calculated by using the Spearman test. A P value < 0.05 was considered as statistically significant. Multivariate correction was performed by using a linear regression model. Gender, age, hypertension, hypercholesterolaemia, diabetes, smoking status, positive family history for cardiovascular disease, hsCRP (highsensitive CRP) levels and BMI <25 or BMI >25 were analysed with a linear regression model. In the CEA study, hsCRP levels were not available, and a positive family history for cardiovascular disease was left out the model because of missing data from 18 patients. All statistical analyses were performed with PASW statistics version 17 (SPSS).
RESULTS
A total of 22 patients in the PCI study and seven patients in the CEA study were excluded from analysis (for details, see the Materials and methods section), leaving data from 78 (PCI study) and 104 patients (CEA study) used for analysis. Clinical characteristics are depicted in Table 1 and  in Supplementary Table S1 (at http://www.clinsci.org/ cs/121/cs1210205add.htm ).
In both studies, TNF-α was used as a specific marker for a TLR response. Several authors have demonstrated the TLR specificity of this cytokine [32, 33] . Stimulation of whole blood samples with PBS did not result in detectable TNF-α levels and, in addition, stimulation Values are medians (IQR), or number of patients (percentage). In both groups, obese patients (BMI >25) were significantly younger compared with non-obese patients.
* P < 0.05 and * * P < 0.001 between the two groups. ACE, angiotensin-converting enzyme; A2, angiotensin II receptor.
PCI study CEA study with the specific TLR2 and TLR4 agonists Pam 3 CSK 4 and LPS resulted in a dose-dependent TNF-α release (results not shown). In both studies, obese patients showed significantly higher TNF-α levels after stimulation of TLR2 compared with non-obese patients [16.9 (7.7-49.4) compared with 7.5 (1.5-19.2) pg/ml (adjusted P value = 0.008) and 14.6 (8.1-28.4) compared with 9.5 (6.1-15.7) pg/ml (adjusted P value = 0.015) for the PCI and CEA study respectively] (Figure 1 ). In the PCI study, TNF-α levels in obese patients were also significantly higher compared with non-obese patients following TLR4 (Figure 1 ). In the PCI study, we observed a trend towards lower levels of TNF-α following TLR2 and TLR4 stimulation in patients who were active smokers compared with patients who did not smoke. However, this trend was not observed in the CEA study (Table 2) . When taking other risk factors into account, we observed no differences in responsiveness between patients without or with these cardiovascular risk factors, statin or antihypertension medication use (Table 2 and Supplementary Table S2 at http://www.clinsci.org/cs/121/cs1210205add.htm).
In the CEA study, we also quantified the levels of IL6 and IL8 following TLR stimulation. Obese patients also had increased levels of IL6 following TLR2 and TLR4 stimulation compared with non-obese patients [7 (3-30) compared with 4 (2-12) pg/ml (adjusted P value = 0.045) and 123 (47-240) compared with 56 (31-133) pg/ml (adjusted P value = 0.054) respectively]. IL8 levels were elevated in obese patients following TLR2 stimulation, but not following TLR4 stimulation [68 (35-147) compared with 37 (23-63) pg/ml (adjusted P value = 0.042) and 560 (306-857) compared with 475 (226-730) pg/ml (adjusted P value = 0.729) respectively] ( Figure 2) .
As a marker for early activation, CD11b expression was measured at baseline in a consecutive subset of patients in both studies. In the PCI and CEA study, the flow cytometry measurements were included in the study protocol at a later time point. In both studies, obese patients revealed increased CD11b expression on CD14 + monocytes, compared with non-obese patients, and these differences were significant in the PCI study ( Figures 3A and 3B ). In the CEA study, we also measured CD11b expression after TLR2 and TLR4 stimulation, and again, obese patients showed increased expression of the activation marker CD11b (Figures 3C  and 3D ). After correction for risk factors, the differences observed between obese and non-obese patients remained significant (P = 0.009 and P = 0.012 after stimulation with LPS and Pam 3 CSK 4 respectively). Differences between groups were not observed after stimulation with an aspecific stimulus, PMA ( Figure 3E ). We did not observe differences in CD11b expression between patients with other established risk factors (Supplementary Table S3 at http://www.clinsci.org/cs/121/cs1210205add.htm). In the PCI study, we measured hsCRP. Obese patients has higher levels of hsCRP (Figure 4) . Finally, TLR2 and TLR4 expression on circulating monocytes were quantified in both studies. In both studies, we did not observe differences in TLR2 and TLR4 expression between obese and non-obese patients. In the PCI study, TLR2 expression was 3.0 (2.4-3.8) and 3.3 (2.8-4.0) pg/ml and TLR4 expression was 2.4 (2.1-3.6) and 2.8 (2.5-3.5) pg/ml in the non-obese and obese patients respectively. In the CEA study, TLR2 expression was 1.5 (0.9-2.5) and 1.8 (1.0-4.3) pg/ml and TLR4 expression was 0.3 (0.2-0.5) and 0.5 (0.3-0.7) pg/ml in the non-obese and obese patients (Supplementary Table  S4 at http://www.clinsci.org/cs/121/cs1210205add.htm). TLR2 and TLR4 expression also did not differ between patients without or with statins or antihypertensive medication (Supplementary Table S5 at http://www.clinsci.org/cs/121/cs1210205add.htm)
DISCUSSION
TLR activation results in an innate immune response and plays an important role in the pathogenesis of atherosclerosis. An association between cardiovascular risk factors and the activation status of the innate immune system, which is reflected by an altered TLR responsiveness, can be suggested. We demonstrate in two cohorts of patients, with established atherosclerosis, that obesity is a cardiovascular risk factor related with an increased TNF-α production by white blood cells following TLR activation.
Obesity and inflammation
While obesity was primarily seen as a lipid storage disease, it is nowadays recognized that obesity should be considered as a chronic inflammatory disorder [16] [17] [18] . Several studies demonstrated that obese patients have increased levels of circulating biomarkers reflecting systemic inflammation [19, 34] . hsCRP is one of the most commonly studied biomarkers and is found to be elevated in obese patients [34] . Our present findings also confirmed that obese patients have increased levels of hsCRP (Figure 3) . Another activation marker of the immune cells is CD11b. CD11b forms together with CD18, the Mac-1 (macrophage-1 antigen or complement receptor 3), and is regarded as a key integrin in mononuclear cell adhesion towards activated endothelium [35] . In both studies, obesity was associated with increased CD11b expression on CD14 + monocytes (Figure 3 ). In the CEA study, CD11b expression was also measured after TLR stimulation, which resulted in significant differences between obese and non-obese patients. Stimulation with the aspecific stimulus PMA (positive control) did not show any differences between obese and non-obese patients.
Zhang et al. [36] showed that physiological levels of NEFAs, which are elevated in obese patients, are able to up-regulate CD11b expression on human monocytes and increase monocyte adherence in an adhesion assay. CD11b is an important adhesion molecule, necessary for firm adhesion of the circulating monocyte to the activated endothelium. Enhanced expression of this integrin therefore might facilitate monocyte entry in 
Obesity and TLR response
In the present study, obesity was the only risk factor that was associated with an increased TLR response. Obese patients have elevated levels of apoCIII (apolipoprotein CIII) and NEFAs, which are able to activate TLR2 and TLR4 respectively [37, 38] . TLRs are mainly expressed on leucocytes, but adipocytes and macrophages in adipose tissue also express these receptors. Release of apoCIII or NEFAs activate TLR2 and TLR4 leading to a pro-inflammatory cytokine production. This might be an explanation of the increased levels of circulating biomarkers reflecting systemic inflammation in obese patients. Secondly, monocytes activated by these elevated levels of apoCIII or NEFAs will express more CD11b and might adhere more easily to the activated endothelium. Because of their already activated state, upon stimulation, these monocytes will produce elevated levels of pro-inflammatory cytokines, resulting in more severe atherosclerosis development.
Obese patients are also at increased risk for developing insulin resistance. In a recent review, Konner and Bruning [39] summarized the abundant evidence that links TLR activation with insulin resistance. An important role for saturated NEFAs causing insulin resistance in a TLRdependent manner was clearly highlighted. Saturated NEFAs are able to activate IKK [inhibitor of NF-κB (nuclear factor-κB) kinase] and JNK (c-Jun N-terminal kinase) in a TLR-dependent manner. Activation of these important kinases not only results into transcription of pro-inflammatory cytokines [via NF-κB and AP-1 (activator protein-1)], but also phosphorylates IRS (insulin receptor substrate) thereby causing insulin resistance. In a large genome-wide association study, Weyrich et al. [40] demonstrated an association between the TLR4 D299G/T399l polymorphism and increased body fat and insulin resistance in two different cohorts, supporting the role of TLR4 as a molecular link between obesity and insulin resistance.
The enhanced responsiveness we observed in obese patients could not be explained by an elevated expression of TLRs on circulating monocytes. Therefore other factors influencing TLR responsiveness might explain the increased responsiveness observed in obese patients. Schwarz et al. [41] demonstrated that saturated NEFAs, which are elevated in obese patients, are able to augment TLR-induced cytokine production in a TLRindependent manner. They showed that the saturated fatty acids lauric acid, palmitic acid or stearic acid are able to augment TLR2 and TLR4 response by stimulation of PKC (protein kinase C). Another possible explanation could be the effect of the anti-inflammatory adipokine adiponectin, levels of which are decreased in obese patients [42] . Yamaguchi et al. demonstrated that adiponectin is able to inhibit TLR2-, TLR4-and TLR9-induced NF-κB activation in murine macrophages [43] . In addition, another study showed decreased IL-6 and TNF-α production of LPS-stimulated porcine macrophages pretreated with adiponectin [44] . Although the exact mechanism is still unknown, the decreased levels of adiponectin in obese patients might explain the observed increased responsiveness in such patients.
Smoking and TLR response
In the PCI study, we observed a trend towards lower levels of TNF-α following TLR stimulation in patients who are active smokers (Table 2) . When taking into account the time patients had stopped smoking, there was a trend towards higher TNF-α levels for patients who had stopped >6 months or had never smoked (Table 2 ). This trend was not observed in the CEA study. Chen et al. [45] showed decreased TLR2 and TLR4 responsiveness in alveolar macrophages isolated from active smokers compared with healthy controls, but failed to demonstrate decreased responsiveness of smokers PBMCs (peripheral blood mononuclear cells), following 6 h of stimulation. We only observed the decreased TLR response in the PCI study, following a longer period of stimulation (o/n incubation). This might explain the differences we observed between our two studies and the study performed by Chen et al.
The strength of our present study is that we demonstrated increased responsiveness in obese patients in two independent cohorts with established atherosclerosis of two different vascular territories. Another strength, which is also a limitation of this study, is the different stimulation times used in both studies. It shows that differences can be observed between obese and nonobese patients despite changes in stimulation duration. On the other hand, we cannot state that we reproduced the results using an identical study design. Secondly, flow cytometry measurements were not performed after TLR stimulation in the PCI study. Finally, our present study is descriptive, and a control group of obese patients without cardiovascular disease is lacking. We can only speculate upon possible explanations for the increased responsiveness observed in obese patients. It would be of great interest to further explore this observation to see whether healthy obese patients, without clearly established atherosclerosis, have also an increased TLR responsiveness. In addition, it would be interesting to see whether more specific markers of activation, such as CD11c, are also elevated in obese patients.
Conclusions
Obese patients with established atherosclerosis show an increased whole blood TLR response and increased expression of the activation marker CD11b.
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Table S1 Additional information on risk factors in both studies
Values are medians (IQR), or number of patients (percentage). Risk factors were scored using the following criteria: hypertension, the use of one or more antihypertensive drugs (>3 months before intervention); hypercholesterolaemia, the use of statins for at least 3 months before intervention; and diabetes, the use of antidiabetic medication (>3 months before intervention). Systolic and diastolic tension, glucose levels and cholesterol, HDL (high-density lipoprotein)-cholesterol, triacylglycerol and LDL (low-density lipoprotein)-cholesterol levels in patients with or without hypertension, diabetes or hypercholesterolemia respectively are depicted.
* P < 0.05, * * P < 0.01 and * * * P < 0.001.
PCI study (n = 78) CEA study (n = 104) 3) (n = 6) 1.4 (0.9-2.5) (n = 53) *
